image

Authoritative Independent Monthly Share Selections Using Technical & Fundamental Analysis

Latest issue now available

SigmaRoc - EBITDA “ahead of budget”

September 2024

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

  • Epic Code:
  • SRC
  • Price:
  • 73p
Interims noted revenues up 62% year-on-year reflecting the first contribution from CRH assets in March,  while EBITDA rose 82% to £100m, ahead of budget. Conditions remain patchy with demand for infrastructure building work and water purification strong, offset by headwinds in residential construction and automotive (impacting demand for steel). However the transformational acquisition of CRH assets is progressing well; deal one (Germany, Czech and Ireland) is fully integrated, Deal 2 (UK) is ahead of schedule and Deal 3 (Poland) is expected to complete end August. Synergies targeting €30m-60m are on track and will improve profitability with EBIT margins forecast by Zeus to increase from 14.5% last year to 15.9% in ’25 and 16.5% i ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X

author